Experimental MDS drug trial halted early after enrolling only 2 patients
NCT ID NCT05148234
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 25 times
Summary
This study tested a drug called BMS-986253 for people with myelodysplastic syndromes (MDS), a group of bone marrow cancers. The goal was to see if the drug was safe and could help control the disease. Only 2 adults enrolled before the study was stopped early, so no conclusions about effectiveness can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.